NewsRoom Articles - Page 5 of 45

FridayFeb 07, 2025 10:00 am

How SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) (NEO: SUNN) (FSE: GY2) Advanced Clean Energy Transition with Community Solar Sites for Honeywell

The transaction value for the unique project, completed last year, included the sale and contracting agreement between Honeywell International and SolarBank, amounting to approximately $41 million. The 21MW DC ground-mount solar power projects, known as SB 13-1, SB 13-2 and SB-14, are located in upstate New York. The projects are expected to operate as community solar sites and be eligible to participate in the NYSUN program to receive NYSERDA incentives. Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (CSE: SUNN) (NEO: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and…

WednesdayFeb 05, 2025 10:00 am

SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) (NEO: SUNN) (FSE: GY2) Intends to Enter Expanding Data Center Market Amid U.S. $500bn USD AI Infrastructure Pledge

SolarBank is pursuing opportunities as a developer, owner and strategic partner in data center infrastructure, a major energy-hungry expansion market fed by the growing AI and general technology drive. The company aims to deliver energy-efficient, carbon-reducing data center solutions that support both immediate needs and long-term growth. The global data center market is seeing exponential growth, expected to reach $395 billion USD by 2030, propelled by surging demand for artificial intelligence, cloud computing, big data analytics, and IoT. SolarBank is joining global tech giants invested in expanding data center capacity, including Amazon, Microsoft, Google, Meta Platforms, and Apple, and building…

WednesdayJan 29, 2025 10:45 am

SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Seals $49.5M USD Deal with Qcells for Four Major Solar Projects in New York

The projects, totaling 25.577 MW, will be developed as community solar initiatives, with SolarBank managing the construction, operation and maintenance of the projects. The projects will use U.S.-manufactured equipment, aligning with Qcells’ investment in domestic solar production, while incentives from New York’s NY-Sun Program will further enhance the projects’ viability. Qcells is investing nearly $2.8 billion USD into boosting U.S. domestic solar manufacturing and innovation to support and accelerate the U.S. clean energy transition. Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (CSE: SUNN) (NEO: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects,…

WednesdayJan 22, 2025 9:30 am

SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) (NEO: SUNN) (FSE: GY2) Secures $25.8M for Battery Storage Projects as Demand Surges

The $25.8 million in financing from the Royal Bank of Canada will be used for two Ontario-based battery energy storage system projects. The projects mark SolarBank’s first foray into energy storage, a market expected to reach $31.2 billion by 2029. Contracts for the projects include a 22-year term with fixed capacity payments significantly above the market average. The projects will benefit from Canada’s Clean Technology Investment Tax Credit, covering up to 30% of eligible capital costs. Battery storage is becoming essential for grid resilience, cost management and meeting skyrocketing energy demand. Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN)…

WednesdayJan 08, 2025 8:00 am

SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) Is ‘One to Watch’

SolarBank has a development pipeline exceeding 1 GW, with over 100 MW of renewable energy projects completed. The company operates a vertically integrated business model, ensuring cost efficiency and maximizing profitability across the project lifecycle. SolarBank recently secured a $25.8 million project finance facility for two BESS projects, demonstrating robust financial backing. Announced expansion into the rapidly growing data center market positions the company to tap into an industry that’s forecast to reach a value of $395 billion by 2030. Leadership with over 100 years of combined experience ensures strong operational expertise and strategic vision. SolarBank’s diverse portfolio spans solar…

FridayDec 06, 2024 8:45 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care

Emerging therapies, advanced diagnostic tools and groundbreaking research are reshaping the fight against cancer. Calidi Biotherapeutics uses stem cells and cell-enveloping technologies to deliver virotherapy payloads that attack cancers and leave healthy cells untouched. RTNova is designed to address the limitations of traditional virotherapy by offering enhanced targeting, systemic delivery and immune system modulation. Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing the global cancer burden, innovation remains critical to achieving further breakthroughs. Emerging therapies, advanced diagnostic…

FridayNov 22, 2024 8:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Shares Data Supporting Innovative Proprietary Systemic Antitumor Platform

“In 2024, over 611,000 deaths from cancer are projected for the U.S.,” the ACA reported. “That’s more than 1,600 deaths from cancer each day.” Calidi Biotherapeutics’ RTNova (“CLD-400”) is an innovative systemic antitumor enveloped virotherapy, designed to unlock new possibilities in cancer therapy. RTNova offers a systemic approach that enables providers to target and treat metastatic tumors that were previously untouchable. The American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United States, after heart disease (https://ibn.fm/ADo2Q).…

FridaySep 20, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations

Lexaria, a global innovator in drug delivery platforms, announced the appointment of Richard Christopher as its new CEO, replacing Chris Bunka who will serve in his new capacity as Executive Strategic Advisor while remaining Chairman of the Board Lexaria also announced entering a Material Transfer Agreement with an undisclosed pharmaceutical industry partner, leading to speculation of which company has taken this formal step to get closer to Lexaria’s technology The company is focusing on this pharmaceutical industry collaboration and on investigations in cardiometabolic and GLP-1 sectors (alternative diabetes and obesity treatments), a huge sector that particularly needs its unmatched technology…

TuesdaySep 17, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study

Lexaria, a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study The study was made up of three main groups of formulations: DehydraTECH-processed CBD; semaglutide (including “Rybelsus(R)”) and liraglutide The DehydraTECH-CBD and DehydraTECH-liraglutide both outperformed Rybelsus(R), which was a surprise outcome. DehydraTECH-liraglutide posted a weight reduction of 4.74%, the most significant in the study For Lexaria, this continued outperformance of DehydraTECH-liraglutide is of particular interest, particularly since many third-party studies have shown semaglutide to be more than twice as effective as liraglutide in promoting weight loss As the study…

ThursdaySep 05, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study

Lexaria, a global innovator in drug delivery platforms, has just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study Two formulations from the study posted outstanding performance, with each utilizing the company’s patented DehydraTECH(TM) technology DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B) posted blood sugar level reductions of 2.50%, 1.90%, and 1.53%, respectively These results build on the positive results from Lexaria’s 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that got no treatment Lexaria Bioscience (NASDAQ:…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000